Indivior Pharmaceuticals, Inc.
- INDV ยท Nasdaq
- Pharmaceutical Preparations
- Rockville, MD
- 838 employees
- CIK 0001625297
Updated from SEC filings through
Top things to know
Revenue, FY2025$1.2B+4.3% vs FY2024Operating margin21.1%Operating income $262MEmployees838As of December 31, 2025
Next earningsNovember 6, 2026Estimated from past filings
Latest 8-KOther eventsFiled November 3, 2026Leadership changeItem 5.02 filedNovember 2, 2026, last 90 days Executives
- Jack A. Khattar Chief Executive Officer 3, 2026-11-04
- Joseph Ciaffoni Chief Executive Officer 4, 2026-06-23
- Timothy C. Dec SVP, Chief Financial Officer 3, 2026-11-04
- Ryan Preblick Chief Financial Officer 8-K, 2026-10-29
- Frank Mottola SVP, Chief Tech. Ops. Officer 3, 2026-11-04
- Jonathan Rubin SVP, Chief Medical Officer 3, 2026-11-04
What leadership is saying
“In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda”
Earnings press release (8-K Ex. 99.1), filed October 29, 2026
Indivior Pharmaceuticals, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Rockville, MD. It trades as INDV on Nasdaq. Revenue was $1.2B in the fiscal year ending December 31, 2025, +4.3% from the year before. It reported about 838 employees. Jack A. Khattar is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.2B 10-K, 2026-02-26 | $1.2B 10-K, 2026-02-26 | $1.1B 10-K, 2026-02-26 | $901M 10-K, 2025-03-03 | Not on file |
| Operating income | $262M 10-K, 2026-02-26 | $38.0M 10-K, 2026-02-26 | -$152M 10-K, 2026-02-26 | -$77.0M 10-Q, 2025-10-30 | $213M 20-F, 2024-03-06 |
| SG&A | $634M 10-K, 2026-02-26 | $612M 10-K, 2026-02-26 | $565M 10-K, 2026-02-26 | $466M 10-Q, 2025-10-30 | Not on file |
| Net income | $210M 10-K, 2026-02-26 | $7.0M 10-K, 2026-02-26 | -$126M 10-K, 2026-02-26 | -$42.0M 10-Q, 2025-10-30 | $205M 20-F, 2024-03-06 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jack A. Khattar | Chief Executive Officer | 3, 2026-11-04 |
| Joseph Ciaffoni | Chief Executive Officer | 4, 2026-06-23 |
| Timothy C. Dec | SVP, Chief Financial Officer | 3, 2026-11-04 |
| Ryan Preblick Chief Financial Officer - Indivior Pharmaceuticals | Chief Financial Officer | 8-K, 2026-10-29 |
| Frank Mottola | SVP, Chief Tech. Ops. Officer | 3, 2026-11-04 |
| Jonathan Rubin | SVP, Chief Medical Officer | 3, 2026-11-04 |
| Padmanabh P. Bhatt | SVP, Chief Scientific Officer | 3, 2026-11-04 |
| William Todd Horich | SVP, Chief Commercial Officer | 3, 2026-11-04 |
| Woodrow D. Anderson | Chief Accounting Officer | 4, 2026-08-27 |
| Christian Heidbreder | Chief Scientific Officer | 4, 2026-07-13 |
| Jeffrey W. Burris | Chief Legal Officer | 4, 2026-03-05 |
 Patrick Barry Chief Commercial Officer and C-Suite Leader | Hyper Growth Strategies | Turnarounds & Transformation | Global Leadership | Board Advisor | Chief Commercial Officer | 10-K, 2026-02-26 |
| Patrick A. Barry | Chief Commercial Officer | 4, 2026-02-12 |
 Vanessa Procter Corporate Affairs Executive | Building Growth-Driving Functions, Shaping Markets and Leading Through Change | EVP for Corporate Affairs | 10-K, 2026-02-26 |
What Indivior Pharmaceuticals, Inc. does
Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 118.0 million (as of October 9, 2026) | 10-Q, October 29, 2026 |
|---|---|---|
| Public float | $1.8B (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, October 29, 2026 |
| Latest proxy statement | Meeting May 13, 2026 (filed March 27, 2026) | DEF 14A, March 27, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Richmond, Virginia) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 27, 2026 | Woodrow D. Anderson Chief Accounting Officer | Buy | 1,500 | $54K | Form 4, August 27, 2026 |
| August 5, 2026 | Woodrow D. Anderson Chief Accounting Officer | Buy | 1,500 | $54K | Form 4, August 5, 2026 |
| July 10, 2026 | Christian Heidbreder Chief Scientific Officer | Sale | 18,586 | $765K | Form 4, July 13, 2026 |
| June 11, 2026 | Christian Heidbreder Chief Scientific Officer | Sale | 18,586 | $707K | Form 4, June 12, 2026 |
| June 8, 2026 | Ryan Preblick Chief Financial Officer | Sale | 36,000 | $1.4M | Form 4, June 10, 2026 |
| March 13, 2026 | Barbara Ryan Director | Buy | 8 | $248.72 | Form 4, March 13, 2026 |
| March 9, 2026 | Barbara Ryan Director | Buy | 31 | $1K | Form 4, March 11, 2026 |
| March 6, 2026 | Stuart A. Kingsley Director | Buy | 940 | $30K | Form 4, March 11, 2026 |
Recent 8-K events
- 8-K filed 2026-11-03
- Item 8.01 Other events
- 8-K filed 2026-11-02
- Item 1.01 Entry into a material definitive agreement
- Item 2.01 Completion of acquisition or disposition of assets
- Item 2.03 Creation of a direct financial obligation
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-10-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-15
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-10-06
- Item 8.01 Other events
- 8-K filed 2026-09-17
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-09-15
- Item 1.02 Termination of a material definitive agreement
- 8-K filed 2026-08-03
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-03
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-03
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Indivior Pharmaceuticals, Inc.
- What does Indivior Pharmaceuticals, Inc. do?
- In its own words, from Item 1 of its 10-K: "Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease."
- What is Indivior Pharmaceuticals, Inc.'s revenue?
- $1.2B for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Indivior Pharmaceuticals, Inc. profitable?
- Indivior Pharmaceuticals, Inc. reported net income of $210M for the fiscal year ending December 31, 2025.
- How many employees does Indivior Pharmaceuticals, Inc. have?
- About 838 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Indivior Pharmaceuticals, Inc.?
- Jack A. Khattar, Chief Executive Officer, as named in a 3 filed November 4, 2026.
- Who is the CFO of Indivior Pharmaceuticals, Inc.?
- Timothy C. Dec, SVP, Chief Financial Officer, as named in a 3 filed November 4, 2026.
- Where is Indivior Pharmaceuticals, Inc. headquartered?
- Rockville, MD.
- What is Indivior Pharmaceuticals, Inc.'s stock ticker?
- INDV on Nasdaq.
- What industry is Indivior Pharmaceuticals, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Indivior Pharmaceuticals, Inc.'s website?
- indivior.com.
- When does Indivior Pharmaceuticals, Inc. report earnings next?
- November 6, 2026. This is an estimate from past filing dates, not a confirmed date.
- Is Indivior Pharmaceuticals, Inc. a public company?
- Yes. Indivior Pharmaceuticals, Inc. files with the SEC under CIK 0001625297 and trades as INDV.
- Who audits Indivior Pharmaceuticals, Inc.?
- PricewaterhouseCoopers LLP, Richmond, Virginia, as named in its latest annual report (10-K).
- How many shares of Indivior Pharmaceuticals, Inc. are outstanding?
- 118.0 million shares as of October 9, 2026, from its 10-Q filed October 29, 2026.
- What is Indivior Pharmaceuticals, Inc.'s public float?
- $1.8B as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Indivior Pharmaceuticals, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed October 29, 2026.
- When is Indivior Pharmaceuticals, Inc.'s annual shareholder meeting?
- May 13, 2026, per its proxy statement (DEF 14A) filed March 27, 2026.
- Have Indivior Pharmaceuticals, Inc. insiders traded stock recently?
- Since January 5, 2026, officers and directors reported 3 open-market sales worth about $2.8M and 10 purchases worth about $312K on Forms 4 and 5. The most recent: Woodrow D. Anderson (Chief Accounting Officer) bought 1,500 shares on August 27, 2026.